Skip to content
Screener

Rigel Pharmaceuticals RIGL Unrealized Gains on Investments

Unrealized Gains on Investments at other companies

Amgen logo
AmgenAMGN
$0—
Nuvation Bio logo
Nuvation BioNUVB
$797K+33.7%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$6K—
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$516K-79.4%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$63.48M+2,930%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
——

Other financials

Income statement

See full
Revenue$58.8M+10.3%
Gross profit$54.2M+10.8%
Operating income$11.9M-7.0%
Net income$8.7M-24.4%
EPS (diluted)$0.44-30.2%

Balance sheet

See full
Cash & equivalents$24.5M-46.6%
Total debt$68.4M+5,079%
Total equity$399.9M+2,054%
Total assets$504.6M+187%

Cash flow

See full
Operating cash flow$2.7M+405%
CapEx$73.0K—
Free cash flow-$22.0M—

Valuation

See full
Market cap$778.2M+29.7%
Enterprise value$822.1M+50.0%
P/E2.1×-4.0×
P/S2.6×+0.4×

Profitability

See full
Gross margin93.4%+3.7pp
Operating margin41.6%+19.9pp
Net margin121.5%+103pp
FCF margin-61.7%—

Returns & leverage

See full
Return on equity174.1%—
Debt / equity0.2×+0.1×
Current ratio2.6×+0.4×

Where this comes from

Reported directly by Rigel Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.

The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:05 PM EDT
Fiscal quarter
Q4 FY2026
Calendar quarter
Q4 2026
Accession
0001034842-26-000032
As of March 31, 2026Amortized CostGross Unrealized GainsGross Unrealized LossesFair Value
US treasury bills$76,554$30$(110)$76,474
Government-sponsored enterprise securities23,1478(42)23,113
Corporate bonds and commercial paper23,7994(18)23,785
Total$123,500$42$(170)$123,372

Item 1. Financial Statements

FAQ

What is Rigel Pharmaceuticals's unrealized gains on investments?
Rigel Pharmaceuticals (RIGL) reported unrealized gains on investments of $42K in Q1 2026.
What does unrealized gains on investments mean?
This reflects the positive change in market value of available-for-sale securities that have not yet been sold. It represents potential future liquidity and unrealized wealth generated from the company's treasury management activities. Monitoring this provides insight into the performance of the firm's investment portfolio relative to market benchmarks.

Ask your AI about Rigel Pharmaceuticals's unrealized gains on investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude